Belite Bio, Inc (BLTE)
| Market Cap | 5.64B +157.5% |
| Revenue (ttm) | n/a |
| Net Income | -90.27M |
| EPS | -2.54 |
| Shares Out | 39.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 333,834 |
| Open | 142.00 |
| Previous Close | 144.46 |
| Day's Range | 138.51 - 146.43 |
| 52-Week Range | 56.10 - 200.00 |
| Beta | -1.24 |
| Analysts | Strong Buy |
| Price Target | 210.50 (+46.84%) |
| Earnings Date | May 20, 2026 |
About BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical dev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price target is $210.5, which is an increase of 46.84% from the latest price.
News
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio Transcript: Stifel 2026 Virtual Ophthalmology Forum
Tinlarebant, an oral therapy for Stargardt disease, showed a 36% reduction in disease progression in phase III trials and is nearing FDA submission. The drug’s unique mechanism targets retinol delivery, with a strong safety profile and potential expansion into geographic atrophy pending further data.
Belite Bio price target lowered to $215 from $223 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Belite Bio (BLTE) to $215 from $223 and keeps an Outperform rating on the shares. The “key takeaway” from the…
Belite Bio Earnings Call Transcript: Q1 2026
NDA rolling submission for Stargardt disease is underway, with commercial launch preparations and strong cash reserves supporting expansion. R&D and SG&A expenses rose sharply year-over-year, driven by clinical and pre-commercial activities. FDA approval remains the top priority.
Belite Bio Earnings release: Q1 2026
Belite Bio released its Q1 2026 earnings on May 20, 2026, summarizing the period's financial results.
Belite Bio Slides: Q1 2026
Belite Bio has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 20, 2026.
Belite Bio reports Q1 non-GAAP EPS (34c), consensus (64c)
As of March 31 the Company had $276.4M in cash and cash equivalents, compared with $352.9M on December 31, 2025. “This has been an exciting start to the year for…
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...
Belite Bio receives orphan drug status for tinlarebant in Switzerland
Belite Bio (BLTE) announced that the Swiss Agency for Therapeutic Products has granted tinlarebant, the company’s lead product candidate, orphan drug status for the treatment of Stargardt disease. Pub...
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel th...
Belite Bio Transcript: Bank of America Global Healthcare Conference 2026
The company is advancing tinlarebant, an oral therapy for Stargardt disease, with phase III data showing a 36% reduction in lesion growth and strong physician enthusiasm. Regulatory submissions are underway, with U.S. approval expected within six months and a $7 billion peak sales opportunity projected.
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel th...
Belite Bio management to meet wit Cantor
Breakfast Meeting to be held in Denver on May 5 hosted by Cantor.
Belite Bio Transcript: Deutsche Bank ADR Virtual Investor Conference
Tinlarebant, an oral therapy for Stargardt disease, achieved a 36% reduction in lesion growth and sustained 80% RBP4 reduction in phase III trials, with strong safety and regulatory progress. The therapy addresses a major unmet need and is positioned for broad application in retinal diseases.
Belite Bio Slides: Company presentation
Belite Bio has posted slides in relation to its latest quarterly earnings report, which was published on April 27, 2026.
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) a clinical stage development company based in San Diego and focused on advancing novel therapeutics targeting degenerative ...
Belite Bio initiates rolling submission of NDA to U.S FDA for tinlarebant
Belite Bio (BLTE) announced that it has initiated a rolling submission of a New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for tinlarebant, an investigational novel…
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that ...
Belite Bio Transcript: Leerink Global Healthcare Conference 2026
Tinlarebant, an oral RBP4 antagonist, showed a 36% reduction in Stargardt disease progression in a global phase III trial, with strong safety and efficacy in both eyes. U.S. and global regulatory filings are underway, and commercialization plans focus on genetic testing and market readiness.
Belite Bio price target raised to $200 from $185 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $200 from $185 and keeps a Buy rating on the shares following the Q4 report. The Phase 3…
Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Belite Bio (BLTE) to $266 from $200 and keeps an Overweight rating on the shares. Recent commentary suggested a possibility of a…
Belite Bio price target raised to $217 from $187 at Benchmark
Benchmark raised the firm’s price target on Belite Bio (BLTE) to $217 from $187 and keeps a Buy rating on the shares. The company “achieved a major catalyst” during Q4…
Belite Bio price target raised to $201 from $191 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Belite Bio (BLTE) to $201 from $191 and keeps an Overweight rating on the shares. The company’s Q4 update…
Belite Bio price target raised to $200 from $195 at BofA
BofA raised the firm’s price target on Belite Bio (BLTE) to $200 from $195 and keeps a Buy rating on the shares. After the company reported FY25 results and provided…